Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• EPR Properties (EPR) Reiterated at Market Outperform by Citizens on Strong Momentum
• Biogen expects $164M R&D charge to hit Q2 2026 earnings